Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARQ-CSU2 Phase 3 barzolvolimab study in chronic spontaneous urticaria
2024-513210-36-00Phase 3Authorised
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Barzolvolimab with Placebo (2 arms). Primary endpoint: Mean change from baseline in UAS7 at Week 12. Planned start Apr 2025; status: authorised.
02
Drugs
barzolvolimab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-513210-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513210-36-00.